Myriad Genetics has signaled renewed growth potential through the rollout of two novel genetic tests in women’s health and neurology this quarter, supplementing its core hereditary cancer franchise. The company’s refreshed Customer Conversion and Commitment (CCC) strategy is targeting a 15% increase in test orders from existing accounts by year-end, leveraging new sales incentives and expanded laboratory capacity. However, revenue continues to face headwinds following the loss of third-party coverage for its GeneSight pharmacogenomics panel, which contributed approximately 10% of total diagnostic revenues last year. Management is exploring alternative reimbursement pathways and expects the coverage gap to narrow by mid-year as payor discussions progress.

On Monday, the shares moved above their 200-day moving average for the first time in five months, accompanied by a daily trading volume jump of more than 40% versus the three-month average. Several brokerage firms have adjusted their outlooks: two upgraded to overweight or neutral based on the company’s de-risked cost structure and pipeline catalysts, while one maintained a sell rating due to ongoing margin pressure. Institutional ownership remains high at over 99%, with recent position increases by two major asset managers who collectively added nearly 2.4 million shares during the fourth quarter. Key balance-sheet metrics include a debt-to-equity ratio below 0.35 and a current ratio exceeding 2.3, supporting financial stability as the company pursues its growth agenda.